Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High – What’s Next?

Roivant Sciences Ltd. (NASDAQ:ROIV)’s stock price hit a new 52-week high on Friday . The stock traded as high as $25.49 and last traded at $24.7320, with a volume of 3598048 shares. The stock had previously closed at $21.14.

Key Headlines Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Positive Phase 2 BEACON results for brepocitinib in cutaneous sarcoidosis — the first industry‑sponsored, placebo‑controlled positive readout in this indication, which strengthens Roivant’s dermatology franchise and is the primary catalyst behind the stock move today. Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
• Positive Sentiment: Pipeline progress: Pulmovant (a Roivant company) completed enrollment in the Phase 2 PHocus study of mosliciguat for PH‑ILD, reducing near‑term execution risk on that program and supporting long‑term value of Roivant’s portfolio. Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study
• Neutral Sentiment: Roivant filed Q3 results and held an earnings call — investors should review the call transcript and slide deck for management commentary on milestones, cash runway, and timelines for upcoming readouts that could drive future moves. Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
• Negative Sentiment: Mixed/weak near‑term financials: the quarter showed a loss and revenue below some analyst expectations (company reported low single‑digit millions in revenue), which creates short‑term earnings pressure despite the clinical wins; watch guidance and cash burn commentary. Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Wall Street Analyst Weigh In

ROIV has been the topic of several research analyst reports. Citigroup lifted their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Roivant Sciences in a report on Thursday, January 22nd. HC Wainwright upped their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Leerink Partners boosted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Stock Up 22.3%

The stock has a market cap of $17.99 billion, a PE ratio of -22.10 and a beta of 1.22. The stock has a fifty day moving average of $22.07 and a 200-day moving average of $17.81.

Insiders Place Their Bets

In related news, insider Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total value of $22,122,381.45. Following the transaction, the insider directly owned 20,267,429 shares in the company, valued at $440,005,883.59. This trade represents a 4.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Richard Pulik sold 406,731 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the completion of the transaction, the chief financial officer directly owned 239,413 shares in the company, valued at $5,370,033.59. This represents a 62.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 12,132,392 shares of company stock valued at $262,349,645. 10.80% of the stock is owned by company insiders.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. Jones Financial Companies Lllp lifted its position in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. SBI Securities Co. Ltd. increased its position in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP raised its stake in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Finally, CWM LLC lifted its holdings in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.